DK2953957T3 - Modificerede glycolipider og fremgangsmåder til fremstilling og brug af disse - Google Patents
Modificerede glycolipider og fremgangsmåder til fremstilling og brug af disse Download PDFInfo
- Publication number
- DK2953957T3 DK2953957T3 DK14706210.3T DK14706210T DK2953957T3 DK 2953957 T3 DK2953957 T3 DK 2953957T3 DK 14706210 T DK14706210 T DK 14706210T DK 2953957 T3 DK2953957 T3 DK 2953957T3
- Authority
- DK
- Denmark
- Prior art keywords
- glycolipides
- preparing
- modified
- methods
- modified glycolipides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762591P | 2013-02-08 | 2013-02-08 | |
| US13/803,972 US9371352B2 (en) | 2013-02-08 | 2013-03-14 | Modified glycolipids and methods of making and using the same |
| US201361842149P | 2013-07-02 | 2013-07-02 | |
| PCT/US2014/015286 WO2014124245A1 (en) | 2013-02-08 | 2014-02-07 | Modified glycolipids and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2953957T3 true DK2953957T3 (da) | 2019-07-22 |
Family
ID=51300153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14706210.3T DK2953957T3 (da) | 2013-02-08 | 2014-02-07 | Modificerede glycolipider og fremgangsmåder til fremstilling og brug af disse |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2953957B1 (da) |
| JP (1) | JP6487854B2 (da) |
| KR (1) | KR102167438B1 (da) |
| CN (1) | CN105339379B (da) |
| AU (1) | AU2014214770B2 (da) |
| CA (1) | CA2900524A1 (da) |
| DK (1) | DK2953957T3 (da) |
| ES (1) | ES2730649T3 (da) |
| NZ (1) | NZ710949A (da) |
| WO (1) | WO2014124245A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| EP2112930B1 (en) | 2007-02-21 | 2017-01-11 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
| CN108530517A (zh) * | 2017-03-01 | 2018-09-14 | 拜西欧斯（北京）生物技术有限公司 | 刺激免疫细胞活化的多肽、融合蛋白及其制备方法 |
| CN107522760A (zh) * | 2017-08-21 | 2017-12-29 | 河南师范大学 | 具有免疫活性的α‑GalCer磷酸酯类化合物及其合成方法 |
| US11559568B2 (en) | 2017-10-27 | 2023-01-24 | Children's Medical Center Corporation | Short chain ceramide-based lipids and uses thereof |
| CA3096398A1 (en) | 2018-04-12 | 2019-10-17 | Children's Medical Center Corporation | Ceramide-like lipid-based delivery vehicles and uses thereof |
| KR102795998B1 (ko) * | 2021-11-19 | 2025-04-16 | 연세대학교 산학협력단 | 결핵균 성장 촉진용 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| WO1998001448A1 (en) | 1996-07-03 | 1998-01-15 | Japan Energy Corporation | Novel purine derivatives |
| ES2235324T3 (es) | 1997-04-10 | 2005-07-01 | Kirin Beer Kabushiki Kaisha | Empleo de a-glicosilceramidas para la obtencion de un agente terapeutico para enfermedades autoinmunes. |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| ATE321859T1 (de) | 1998-06-10 | 2006-04-15 | Us Gov Health & Human Serv | B2microglobulin fusionsproteine und varianten mit hoher affinität |
| CA2453880A1 (en) | 2001-07-25 | 2003-02-06 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| CA2493690C (en) | 2002-06-13 | 2011-11-08 | New York University | Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases |
| CA2500478A1 (en) | 2002-09-27 | 2004-04-08 | Biomira, Inc. | Glycosylceramide analogues |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| EP2343306B1 (en) | 2003-02-14 | 2018-04-04 | Japan as represented by President of National Center of Neurology and Psychiatry Ministry of Health | Glycolipid derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates |
| GB0314682D0 (en) | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
| JP2005089334A (ja) | 2003-09-12 | 2005-04-07 | Sumitomo Pharmaceut Co Ltd | ８−ヒドロキシアデニン化合物 |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| EP1728792A4 (en) | 2004-03-26 | 2010-12-15 | Dainippon Sumitomo Pharma Co | 8-OXOADENINE COMPOUND |
| ES2563952T3 (es) | 2004-03-26 | 2016-03-16 | Sumitomo Dainippon Pharma Co., Ltd. | Compuesto de 8-oxoadenina 9-sustituido |
| US8022043B2 (en) | 2004-08-27 | 2011-09-20 | Albert Einstein College Of Medicine Of Yeshiva University | Ceramide derivatives as modulators of immunity and autoimmunity |
| AU2005280163B2 (en) * | 2004-08-27 | 2011-11-24 | Albert Einstein College Of Medicine, Inc. | Ceramide derivatives as modulators of immunity and autoimmunity |
| EP1833489A4 (en) * | 2004-12-28 | 2011-08-03 | Univ Rockefeller | GLYCOLIPIDES AND ANALOGUE THEREOF AS ANTIGENS FOR NK-T CELLS |
| US20070292418A1 (en) | 2005-04-26 | 2007-12-20 | Eisai Co., Ltd. | Compositions and methods for immunotherapy |
| EP1998759A2 (en) | 2006-03-23 | 2008-12-10 | Schering Corporation | Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto |
| EP2112930B1 (en) * | 2007-02-21 | 2017-01-11 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
| KR20110137290A (ko) | 2009-01-08 | 2011-12-22 | 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 | 세포벽 결합 세라미드 유사 당지질을 갖는 박테리아 백신 및 이의 용도 |
-
2014
- 2014-02-07 NZ NZ710949A patent/NZ710949A/en not_active IP Right Cessation
- 2014-02-07 KR KR1020157024435A patent/KR102167438B1/ko active Active
- 2014-02-07 CA CA2900524A patent/CA2900524A1/en not_active Abandoned
- 2014-02-07 ES ES14706210T patent/ES2730649T3/es active Active
- 2014-02-07 WO PCT/US2014/015286 patent/WO2014124245A1/en not_active Ceased
- 2014-02-07 JP JP2015557115A patent/JP6487854B2/ja not_active Expired - Fee Related
- 2014-02-07 CN CN201480019636.9A patent/CN105339379B/zh not_active Expired - Fee Related
- 2014-02-07 EP EP14706210.3A patent/EP2953957B1/en active Active
- 2014-02-07 DK DK14706210.3T patent/DK2953957T3/da active
- 2014-02-07 AU AU2014214770A patent/AU2014214770B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| NZ710949A (en) | 2020-02-28 |
| ES2730649T3 (es) | 2019-11-12 |
| KR20150119019A (ko) | 2015-10-23 |
| WO2014124245A1 (en) | 2014-08-14 |
| CA2900524A1 (en) | 2014-08-14 |
| AU2014214770B2 (en) | 2018-09-06 |
| CN105339379A (zh) | 2016-02-17 |
| KR102167438B1 (ko) | 2020-10-19 |
| EP2953957B1 (en) | 2019-04-10 |
| JP2016509013A (ja) | 2016-03-24 |
| JP6487854B2 (ja) | 2019-03-20 |
| CN105339379B (zh) | 2019-11-26 |
| AU2014214770A1 (en) | 2015-08-27 |
| EP2953957A1 (en) | 2015-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289821B (en) | Compositions and methods for immunotherapy | |
| DK3079719T3 (da) | ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3227336T3 (da) | Anti-CD79b-antistoffer og fremgangsmåder til anvendelse | |
| DK2970460T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
| DK3540429T3 (da) | Indretning og fremgangsmåder til anvendelse af indretning til detektion af hyperammoniæmi | |
| DK3003039T3 (da) | Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser | |
| DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
| DK2970456T3 (da) | Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer | |
| DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
| DK3027209T3 (da) | Anti-Activin A-antistoffer og anvendelser deraf | |
| DK3043784T3 (da) | Arylethere og anvendelser deraf | |
| DK3050641T3 (da) | Fremgangsmåde og indretning til dannelse af riller i rørelementer | |
| DK2800565T3 (da) | Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| DK3116911T3 (da) | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse | |
| DK3014157T3 (da) | Fleksibelt rør og tilhørende fremgangsmåde | |
| DK3083680T3 (da) | Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse | |
| DK3086807T3 (da) | Antistoffer og fremgangsmåder til anvendelse | |
| DK3063144T3 (da) | Antiparasitære og pesticid-isoxazolinforbindelser | |
| IL285527A (en) | Compositions and methods for immunotherapy | |
| DK3363805T3 (da) | Fremgangsmåder til syntese af sphingomyeliner og dihydrosphingomyeliner | |
| DK3065771T3 (da) | Fremgangsmåder og sammensætninger til vedvarende immunterapi | |
| DK2962100T3 (da) | Tuberkulosebiomarkører og anvendelser deraf | |
| DK3030549T3 (da) | Pyridazinonforbindelser og anvendelser deraf | |
| DK3008852T6 (da) | System og fremgangsmåde til kryptering |